The latest announcement is out from Arbutus Biopharma ( (ABUS) ).
On February 24, 2025, all members of Arbutus Biopharma’s Board of Directors resigned, and five new directors were appointed, including Lindsay Androski as the new CEO. These changes are intended to refocus the company on advancing its pipeline and maximizing contributions to LNP delivery technology, with an expectation of delivering greater value to shareholders and patients. The company will temporarily pause participation in investor meetings while reviewing development plans for its hepatitis B programs.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is developing imdusiran (AB-729) for chronic hepatitis B and aims to maximize opportunities for its Lipid Nanoparticle (LNP) delivery technology through its stake in Genevant.
YTD Price Performance: 1.52%
Average Trading Volume: 743,016
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $632.9M
Learn more about ABUS stock on TipRanks’ Stock Analysis page.